Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A high-tech camera may take the guesswork out of spotting a dangerous surgery complication

NCT ID NCT04796493

Diagnosis Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether two imaging tools—laser speckle contrast imaging (LSCI) and digital thermography—can objectively grade mesenteric traction syndrome (MTS), a frequent complication during abdominal surgery that causes low blood pressure, rapid heart rate, and facial flushing. Currently, MTS severity is judged subjectively by the surgical team, which is unreliable. The trial will measure facial perfusion in about 98 patients undergoing open or robotic surgery for esophageal, gastric, or pancreatic cancer, and compare the two imaging methods against blood biomarkers to see if they can accurately identify and grade MTS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Laser Speckle Contrast Imaging (LSCI) and digital thermography for measuring facial perfusion
What this could lead to
If LSCI and thermography prove interchangeable, surgeons could objectively grade MTS severity using a simple, cheap camera, improving postoperative care.
What could go wrong
The trial is small and observational, and LSCI was not feasible in robotic surgeries, limiting generalizability. Results may not change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

98 people

The number who actually took part.

Started

Mar 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

3 cohorts * open esophagectomies * robotic assisted esophagectomies * whipples procedure

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing curative surgery for esopageal, gastric, doudenal or pancreatic cancer Exclusion Criteria: * Known flushing disease * Patients recieving NSAID and corticosteroid presurgery, Whipple is allowed to recieve single dose of 125 mg Methylprednisone as part of the standard of care at our facility. * Palliative surgery * Surgery not completed due to disseminated disease - patients will still be used in examination of LSCI and Thermography analysis even if desiminated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Duodenal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of duodenum esophageal cancer gastric cancer malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mesenteric traction syndrome

Contacts and locations

Locations

  • Rigshospitalet

    København Ø, Capital Region, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.